Neuro oncology News and Research

RSS

St. Luke’s offers Frameless Stereotactic Radiosurgery for treatment of brain tumors

Some treatments for brain and spine tumors traditionally have involved restraining a patient with a heavy immobilization device and pins that pierce the skin and embed into the skull to ensure the accuracy and precision of a treatment. Doctors say the pins can add considerable anxiety.

20 Jan 2015

UT Southwestern researchers find new potential target for halting tumor growth

UT Southwestern Medical Center researchers have discovered that brain tumors are capable of burning acetate for fuel, providing a new potential target for halting tumor growth.

19 Dec 2014

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma.

12 Dec 2014

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer.

8 Dec 2014

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

23 Nov 2014

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone.

17 Nov 2014

UH's Neurological Institute designated as Gold Center of Excellence

The Neurological Institute at University Hospitals has been designated as a Gold Center of Excellence (COE) and featured as a top performing center by NeuStrategy, Inc., a Chicago consulting firm providing strategic support to neuroscience, oncology and orthopaedic service providers.

23 Oct 2014

Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center.

15 Sep 2014

HICCC receives $18 million grant from the National Cancer Institute

Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI).

28 Aug 2014

Use of VISIUS iMRI in brain tumor surgery results in complete tumor removal

IMRIS Inc. today announced that a recently published article in the journal Neurosurgery is the highest level clinical evidence to show that the use of VISIUS® intraoperative MRI in brain tumor surgery results in complete tumor removal in more patients with glioma tumors.

26 Aug 2014

Researchers find why certain glioblastomas become drug resistance

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas - the primary form of a deadly brain cancer - are resistant to drug therapy.

26 Aug 2014

New web-based program helps to determine deadly form of brain cancer

A new web-based program developed by University of Kentucky Markey Cancer Center researchers will provide a simple, free way for healthcare providers to determine which brain tumor cases require testing for a genetic mutation.

20 Aug 2014

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers.

14 Aug 2014

Kids are at risk of biological damage results from microwave radiation emitted by wireless devices

A scholarly article on wireless safety, published online in the Journal of Microscopy and Ultrastructure, reports that children and fetuses are the most at risk from neurological and biological damage that results from microwave radiation emitted by wireless devices, due to the higher rate of absorption of microwave radiation by children than by adults.

6 Aug 2014

Adopting a comprehensive and integrative healing strategy for cancer

The cancer drugs, radiation therapy and cancer surgery available today help millions of people survive their cancer.

27 Jul 2014

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014.

28 Jun 2014

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system.

26 Jun 2014

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.

2 Jun 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.